Pharmacoeconomics of Parenteral Nutrition with ω‐3 Fatty Acids in Hospitalized Adults

Abstract

The inclusion of ω‐3 fatty acids as part of parenteral nutrition is associated with clinical benefits such as a reduced likelihood of infectious complications and shorter hospital and intensive care unit (ICU) stays. As healthcare resources are limited, pharmacoeconomic analyses have been performed, typically modeling studies, using cost and outcomes data to investigate the cost‐effectiveness of parenteral nutrition regimens including ω‐3 fatty acids from fish oil compared with standard parenteral nutrition without such ω‐3 fatty acids. This review covers pharmacoeconomic studies encompassing Italian, French, German, and UK hospitals for ICU and non‐ICU hospitalized patients, and for ICU patients in China. The results show that the use of parenteral nutrition including ω‐3 fatty acids more than offsets any additional acquisition costs in all national scenarios investigated to date, indicating that parenteral nutrition including ω‐3 fatty acids is a clinically and economically beneficial strategy compared with standard parenteral nutrition.

Expert Opinion on Benefits of Long-Chain Omega-3 Fatty Acids (DHA and EPA) in Aging and Clinical Nutrition

“…Mortality was lower with 16%, but the difference did not reach significance (20 studies: RR 0.84, 95% CI 0.65 to 1.07; p = 0.15) [216]. Moreover, fish oil was found to be more cost-effective than parenteral nutrition with a standard intravenous lipid emulsion [220].…”

Summary of Proceedings and Expert Consensus Statements From the International Summit “Lipids in Parenteral Nutrition”

“…Thus, the cost-effectiveness of various IV lipid emulsions is an important consideration when assessing therapeutic options, 121,122 and so these pharmacoeconomic aspects have also been reviewed in this supplement. 123 Discrete-event simulation models that incorporate evidence-based clinical data and cost estimates derived from local sources are recognized as a useful method for evaluating health economic outcomes. 124,125 Pharmacoeconomic evaluations comparing lipid emulsions containing ω-3 fatty acids with standard lipid emulsions in critically ill and surgical populations have shown that using IV lipid emulsions containing ω-3 fatty acids is a cost-effective strategy in patients who require PN.…”

“…The management of patients who require PN represents a substantial source of healthcare resource consumption. Thus, the cost‐effectiveness of various IV lipid emulsions is an important consideration when assessing therapeutic options, and so these pharmacoeconomic aspects have also been reviewed in this supplement . Discrete‐event simulation models that incorporate evidence‐based clinical data and cost estimates derived from local sources are recognized as a useful method for evaluating health economic outcomes …”

Expert suggestions on nutrition therapy for severe COVID-19 patients

“…肠外营养更易 改善营养状况, 在疾病治疗和帮助患者成功脱离呼吸 机方面也有积极作用, 有助于患者渡过危险期, 促进 康复 [55,63] , 但要实时监测代谢状况, 动态调整给予量, 防止过度喂养 [64] . , 改善 气体交换 [66] , 降低感染并发症, 缩短住院时间及ICU时 间, 同时表现出显著的卫生经济效益 [67] . ω-6:ω-3=2.1:1 的免疫中性效应可延长移植器官的存活时间 [68] .…”